Experimental study of <sup>188</sup>Re-BAC<sub>5</sub> radioimmunotherapy on nasopharyngeal carcinoma

WANG Guohui  LIU Changzheng  LIANG Changsheng

doi:null

您当前的位置：

首页 >

文章列表页 >

Experimental study of ¹⁸⁸Re-BAC₅ radioimmunotherapy on nasopharyngeal carcinoma

更新时间：2021-03-12

- Experimental study of ¹⁸⁸Re-BAC₅ radioimmunotherapy on nasopharyngeal carcinoma
- NUCLEAR TECHNIQUES Issue 5, (2003)
- 作者机构：
  
  1. 中山大学中山医学院核医学教研室
  2. 中山大学肿瘤防治中心核医学科,广州,510080
  3. ,广州,510060
- 作者简介：
- 基金信息：
  
  国家自然科学基金(30070231);广东省自然科学基金(940486)资助
- DOI：
  CLC： R739.63
- Published：01 May 2003
- 稿件说明：
移动端阅览
[1]王国慧,刘长征,梁昌盛,樊卫.~(188)Re-BAC_5对鼻咽癌细胞影响的实验研究[J].核技术,2003(05):375-379.

WANG Guohui LIU Changzheng LIANG Changsheng. Experimental study of ¹⁸⁸Re-BAC₅ radioimmunotherapy on nasopharyngeal carcinoma[J]. Nuclear techniques, 2003, (5): 375-379.
[1]王国慧,刘长征,梁昌盛,樊卫.~(188)Re-BAC_5对鼻咽癌细胞影响的实验研究[J].核技术,2003(05):375-379. DOI：

WANG Guohui LIU Changzheng LIANG Changsheng. Experimental study of ¹⁸⁸Re-BAC₅ radioimmunotherapy on nasopharyngeal carcinoma[J]. Nuclear techniques, 2003, (5): 375-379. DOI：

摘要

采用直接标记法制备188Re-BAC5

并测定标记物的免疫活性

应用噻唑蓝（MTT）法观察188Re-BAC5对体外单层培养的鼻咽癌细胞（CNE-2）的抑制作用。建立鼻咽癌（NPC）肿瘤多细胞微球模型

观察188Re-BAC5对微球生长的抑制和破坏作用。对照组为188Re-BSA、188ReO4。结果显示:188Re-BAC5的标记率在80%以上

标记后的免疫活性分数为61%±15%。MTT法结果表明

188Re-BAC5组的抑瘤率比对照组明显提高（P<0.05）;在肿瘤多细胞微球的抑制实验中

188Re-BAC5对微球生长有强烈的抑制和破坏作用

疗效明显优于对照组。本实验提示

188Re-BAC5有可能在对人鼻咽癌的放射免疫治疗中起到良好的作用。

Abstract

The feasibility of radioimmunotherapy for NPC with 188Re-BAC5

a kind of monoclonal antibody to NPC

was investigated. The 188Re-BAC5 was prepared by direct labeling method and its biological activity was determined. The MTT method was used to determine the inhibition effect of the 188Re-BAC5 on CNE-2 cell line culture

and the destruction effect on CNE-2 multicellular spheroids model was also observed. The control group were 188Re-BSA and 188ReO4-. The biological activity of BAC5 was 1:780000 after purification. The labeling yield of 188Re-BAC5 was above 80%. The immuno-activity of 188Re-BAC5 was 61%±15%. The results of MTT showed that the inhibition ef-fect of 188Re-BAC5 group was much stronger than the control group (P<0.05). In the experiment of tumor multi-cellular spheroids

188Re-BAC5 had a obvious destruction effect on spheroids

and there was a significant dif-ference between 188Re-BAC5 and the control group. In conclusion

188Re-BAC5 may serve a possible way in the treat-ment of NPC in the near future.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

¹⁸⁸Re-7E11C5.3 radioimmunotherapy on human prostate cancer xenograft in nude mice

Experimental study on the labeling of antisense oligonucleotide from U87-EGFRvIII glioma cells with 188Re

Synthesis and radiolabelling of ¹⁸⁸Re labeled dendrimer PAMAM-folic acid conjugate

Recent progresses in ¹⁸⁸Re labeling biomolecules

¹⁸⁸Re labeling of prostate cancer monoclonal antibody and its biodistribution in tumor-bearing nude mice

Related Author

ZHANG Yong1 XU Jiehua1 CHEN Weizhen1 LU Hanping2 LIANG Changsheng3 ZOU Juntao4 XIE Yao4 LIU Changzheng2 1

许杰华

陈维真

卢汉平

梁昌盛

邹俊涛

谢瑶

刘长征

Related Institution

中山大学基础医学院人体解剖学教研室

中山大学基础医学实验教学中心

中山大学基础医学院实验核医学教研室

Department of Nuclear Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China) 2

Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University

AI问答

Address：2019 Jialuo Road, Jiading, Shanghai, China Postal code：201800
Tel：021-39194977 Email：LHB@sinap.ac.cn
Technical support is provided by Beijing Founder electronics co., LTD 沪ICP备05005479号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
Total Visits：881003 Visits Today：530

⁰

Experimental study of 188Re-BAC5 radioimmunotherapy on nasopharyngeal carcinoma

DOI：

摘要

Abstract

关键词

Keywords

references

Experimental study of ¹⁸⁸Re-BAC₅ radioimmunotherapy on nasopharyngeal carcinoma